Norethisterone enanthate

Norethisterone enanthate
Clinical data
Trade names Noristerat, Norigest
AHFS/Drugs.com International Drug Names
Routes of
administration		 Intramuscular injection
Legal status
Legal status
  • AU: S4 (Prescription only)
Identifiers
Synonyms SH-393
CAS Number 3836-23-5 YesY
PubChem (CID) 229295
ChemSpider 199613 N
ChEMBL CHEMBL1201146 N
Chemical and physical data
Formula C27H38O3
Molar mass 410.588 g/mol
 NYesY (what is this?)  (verify)

Norethisterone enanthate (NETE) (INN, BAN) (brand names Noristerat, Norigest, others), also known as norethindrone enanthate (USAN), is a steroidal progestin of the 19-nortestosterone group with additional weak androgenic and estrogenic activity[1] that is used as a hormonal contraceptive.[2][3] It is given by intramuscular injection, via which it acts as a long-lasting depot.[4] The drug has been approved in more than 40 countries worldwide,[5] including in the United Kingdom, Europe, Central America, and Africa,[6] though notably not in the United States.[7][8] NETE is the enanthate ester of norethisterone,[4] and acts as a prodrug to it.[9] It was developed in 1956,[10] and was introduced by Schering as Noristerat in 1957.[7] The drug was the first progestogen-only injectable contraceptive, preceding medroxyprogesterone acetate (Depo-Provera).[7]

See also

References

  1. ↑ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 417–. ISBN 978-92-832-1291-1. Norethisterone and its acetate and enanthate esters are progestogens that have weak estrogenic and androgenic properties.
  2. ↑ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1450. ISBN 978-0-412-46630-4. Retrieved 12 May 2012.
  3. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 750. ISBN 978-3-88763-075-1. Retrieved 30 May 2012.
  4. 1 2 Wu L, Janagam DR, Mandrell TD, Johnson JR, Lowe TL (2015). "Long-acting injectable hormonal dosage forms for contraception". Pharmaceutical Research. 32 (7): 2180–91. doi:10.1007/s11095-015-1686-2. PMID 25899076.
  5. ↑ Luigi Mastroianni; Peter J. Donaldson; Thomas T. Kane; Committee on Contraceptive Development (U.S.) (1 January 1990). Developing New Contraceptives: Obstacles and Opportunities. National Academies. pp. 38–. NAP:14119. Cite uses deprecated parameter |coauthors= (help)
  6. ↑ Amy Whitaker; Melissa Gilliam (27 June 2014). Contraception for Adolescent and Young Adult Women. Springer. pp. 96–. ISBN 978-1-4614-6579-9.
  7. 1 2 3 Vern L. Bullough (2001). Encyclopedia of Birth Control. ABC-CLIO. pp. 145–. ISBN 978-1-57607-181-6.
  8. ↑ Ellen H. Moskowitz; Bruce Jennings (13 September 1996). Coerced Contraception?: Moral and Policy Challenges of Long Acting Birth Control. Georgetown University Press. pp. 40–. ISBN 1-58901-807-9.
  9. ↑ Edelman AB, Cherala G, Stanczyk FZ (2010). "Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review". Contraception. 82 (4): 314–23. doi:10.1016/j.contraception.2010.04.016. PMID 20851224.
  10. ↑ WIED GL, DAVIS ME (1958). "Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates". Ann. N. Y. Acad. Sci. 71 (5): 599–616. PMID 13583817.



This article is issued from Wikipedia - version of the 12/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.